Diabetes Care Devices Market By Device Category (Glucose Meters, CGM, Insulin Pumps); By Technology (Connected, Non-connected); By Usage Mode (Continuous, Spot-check); By Patient Type (Type 1, Type 2); By Distribution Channel (Retail Pharmacy, DME, Online); By Data Integration (Standalone, App-connected, Cloud-integrated); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Diabetes Care Devices Market size was estimated at USD 29,384.61 million in 2025 and is expected to reach USD 49,607.36 million by 2032, growing at a CAGR of 9.12% from 2025 to 2032. Rising diabetes prevalence and earlier diagnosis are increasing daily monitoring intensity and driving sustained demand for both glucose monitoring and insulin delivery technologies across home-care settings. Wider access to connected platforms and reimbursement support in major markets is improving adoption of continuous monitoring and automated insulin delivery workflows.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Diabetes Care Devices Market Size 2025
USD 29,384.61 million
Diabetes Care Devices Market, CAGR
9.12%
Diabetes Care Devices Market Size 2032
USD 49,607.36 million
Key Market Trends & Insights
The Diabetes Care Devices Market is projected to expand at a CAGR of 9.12% (2025–2032), reflecting strong momentum in wearable monitoring and therapy optimization.
North America accounted for 41.7% (2025), supported by high penetration of advanced glucose monitoring and stronger reimbursement coverage for diabetes technologies.
Asia Pacific represented 24.6% (2025), driven by a large patient base, improving access to diagnostics, and growing adoption of connected care pathways.
Type 2 accounted for the largest share of 63.8% in 2025, reflecting the broad prevalence base and recurring monitoring needs across treated populations.
The market is expected to reach USD 49,607.36 million by 2032, supported by continued device upgrades, expanded channel access, and ecosystem-based product strategies.
Segment Analysis
Diabetes care devices demand is shaped by the shift from episodic glucose checks toward continuous monitoring and data-driven management. Patients and clinicians increasingly prefer solutions that reduce uncertainty through alerts, trend visibility, and standardized reporting that supports therapy adjustments. Device ecosystems that simplify onboarding, improve wear comfort, and integrate dosing and nutrition context are strengthening adherence and increasing repeat utilization.
Care delivery models also influence purchase pathways and product selection. Retail and online channels support broader access for monitoring supplies and entry devices, while durable medical equipment channels remain important for reimbursed devices that require training and ongoing support. Data integration is becoming a meaningful differentiator as platforms compete on app experiences, remote sharing, and workflow compatibility for population management.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Glucose monitoring remains central to diabetes management because routine tracking supports immediate behavioral decisions and longer-term therapy optimization. CGM adoption benefits from real-time visibility and alerts that reduce hypoglycemia risk and support day-to-day engagement. Insulin pumps gain traction where therapy intensification requires precision dosing and where automated insulin delivery improves time-in-range. Product differentiation continues to focus on accuracy, wear duration, ease of use, and ecosystem interoperability.
By Technology Insights
Connected solutions are increasingly preferred because they enable data sharing, coaching support, and remote monitoring workflows that align with chronic-care management. App experiences and onboarding simplicity influence adoption, particularly for new users transitioning from conventional monitoring routines. Non-connected devices retain demand in cost-sensitive settings and for users prioritizing simple workflows. Vendors increasingly position portfolios to address both premium connected care and value-focused entry devices.
By Usage Mode Insights
Continuous use aligns with the growing adoption of wearable monitoring and integrated therapy systems that rely on persistent data streams. Continuous monitoring supports proactive management through alerts and trend interpretation, which can improve patient confidence and clinician decision-making. Spot-check usage remains common for routine monitoring, especially among non-insulin users and settings focused on affordability. Clinical practice patterns and coverage decisions shape the pace of migration from spot-check to continuous routines.
By Patient Type Insights
Type 2 accounted for the largest share of 63.8% in 2025. The large prevalence base sustains recurring demand for monitoring devices and consumables, particularly as screening and treatment initiation expand. Progression to insulin therapy increases interest in advanced monitoring and dose-support tools that improve control and reduce complications. Technology adoption is also supported by structured education and care-team engagement models that reinforce sustained use.
By Distribution Channel Insights
Retail pharmacies play a major role in accessibility because they enable convenient replenishment of monitoring supplies and broad availability of entry devices. Online channels continue to expand through home delivery, subscription-style replenishment, and simplified purchasing pathways for chronic-care needs. DME remains important for reimbursed devices that require training, documentation, and follow-up support. Channel strategy increasingly emphasizes availability, affordability, and patient support services to reduce drop-off.
By Data Integration Insights
Standalone usage remains relevant where smartphone access, digital literacy, or connectivity constraints limit adoption of app-based workflows. App-connected devices improve engagement through alerts, trend visualization, and simplified reporting that supports daily decision-making. Cloud-integrated platforms strengthen clinician visibility and enable remote review, which supports titration and population-based care programs. Competition is intensifying around interoperability, data security expectations, and workflow compatibility across care settings.
Diabetes Care Devices Market Drivers
Rising diabetes prevalence and earlier diagnosis
Growing diabetes incidence and improved screening are expanding the population that requires routine glucose monitoring and therapy adjustments. Earlier diagnosis increases the duration of device use over a patient’s lifetime, strengthening recurring demand for monitoring systems and supplies. Clinicians increasingly encourage structured monitoring routines to improve glycemic control and reduce complications. As patient counts rise, demand scales across both entry monitoring and advanced connected platforms.
For instance, Abbott’s FreeStyle Libre system surpassed 5 million active global users, with its sensors delivering glucose readings every minute and reducing time spent in hypoglycemia by up to 38% in clinical studies.
Shift toward continuous monitoring and proactive management
Wearable monitoring enables real-time glucose visibility and alerts that help patients respond sooner to glycemic excursions. Continuous data supports education, behavioral reinforcement, and more informed clinical decision-making. This shift increases device utilization intensity and supports upgrades from conventional monitoring to more advanced systems. The move toward proactive management also elevates the value of data integration and user-friendly experiences.
For instance, Dexcom G7 provides glucose readings every 5 minutes (288 readings per day) with a mean absolute relative difference (MARD) of 8.2%, enabling high-accuracy real-time alerts and reducing HbA1c levels by approximately 1.2 percentage points in controlled trials.
Expansion of connected ecosystems and digital diabetes care
App and cloud connectivity support remote monitoring, clinician collaboration, and coaching pathways that align with chronic disease management programs. Data sharing reduces friction in follow-up care and enables more consistent therapy optimization. Vendors differentiate through platform features, compatibility across devices, and integration into care workflows. Connected care also supports scalable programs that can improve adherence and persistence.
Broader access through diversified channels and reimbursement support
Retail, DME, and online channels expand reach by supporting both reimbursed device fulfillment and direct purchasing for monitoring supplies. As coverage expands in major markets, eligible populations gain access to higher-value technologies. Patient support services and training reduce early discontinuation and improve outcomes. Channel coverage and service quality increasingly influence brand selection and long-term retention.
Diabetes Care Devices Market Challenges
Pricing pressure and reimbursement constraints can limit adoption of advanced monitoring and automated insulin delivery, particularly in cost-sensitive settings. Coverage criteria may restrict access to certain technologies, leading to uneven penetration across patient subgroups. Supply reliability and sensor availability can also affect continuity for users reliant on continuous monitoring. These factors can slow upgrades and increase switching behavior.
For instance, Senseonics’ Eversense E3 implantable CGM system offers a sensor lifespan of up to 180 days, significantly longer than traditional 10–14 day sensors, but its adoption has been limited in several regions due to reimbursement restrictions and the requirement for minor in-clinic procedures, which affects scalability compared to fully disposable CGM systems.
Data privacy expectations, interoperability requirements, and workflow integration add complexity for connected ecosystems. Devices must meet stringent quality and accuracy expectations while supporting secure data sharing across apps and cloud platforms. User onboarding and sustained engagement remain challenging, especially for populations with varying digital literacy. Competitive intensity increases the need for consistent product performance and differentiated services.
Market Trends and Opportunities
Expansion of consumer-friendly monitoring models is increasing demand for simpler onboarding, clearer insights, and improved comfort and wear experiences. Opportunities grow for vendors that combine monitoring hardware with compelling software features that reinforce daily use. Partnerships with digital health platforms can strengthen care-team engagement and improve therapy optimization. Product road maps increasingly prioritize ecosystem interoperability and convenient channel access.
Emerging-market health system modernization supports long-term opportunities as diagnosis rates improve and access to monitoring expands. Local distribution strength, affordability-focused portfolios, and education programs can improve adoption and persistence. Innovation in dosing support, analytics, and remote monitoring enables new service models that appeal to payers and employers. Vendors that align products to both premium and value segments can broaden addressable demand.
For instance, Sanofi offers a dual portfolio strategy with Toujeo (long-acting insulin with up to 36-hour duration) targeting premium segments, alongside its Insuman range designed for cost-sensitive markets, enabling wider patient coverage across income groups.
Regional Insights
North America
North America accounted for 41.7% of the Diabetes Care Devices Market in 2025, supported by strong adoption of advanced glucose monitoring and insulin delivery technologies. Established reimbursement pathways and broad clinician familiarity with device-driven care support higher utilization. Competitive intensity is elevated as brands compete on ecosystem compatibility, user experience, and training support. Retail and DME channels remain important for access, while online purchasing supports convenient replenishment.
Europe
Europe represented 27.9% of the Diabetes Care Devices Market in 2025, supported by structured care pathways and growing demand for connected monitoring in eligible populations. Procurement discipline places emphasis on value demonstration, reliability, and outcomes-oriented use. Adoption varies by country based on reimbursement depth and care pathway design, shaping portfolio and channel strategies. Companies compete through clinical evidence, platform features, and service quality.
Asia Pacific
Asia Pacific held 24.6% of the Diabetes Care Devices Market in 2025, driven by a large patient base, improving diagnosis rates, and increasing access to monitoring supplies. Growing middle-class spending and expansion of modern retail and e-commerce support device penetration. Uptake of connected monitoring is rising, supported by higher smartphone usage and stronger interest in self-management tools. Vendors prioritize affordability ladders, distribution partnerships, and education efforts to support sustained use.
Latin America
Latin America accounted for 3.9% of the Diabetes Care Devices Market in 2025, supported by growth in private-sector care access and improving retail availability in major countries. Adoption tends to concentrate in urban areas where diagnostics and specialty care are more accessible. Value-focused portfolios and channel coverage are key to scaling access across broader populations. Online channels are gaining relevance where delivery logistics and payment options support recurring purchases.
Middle East & Africa
Middle East & Africa represented 1.9% of the Diabetes Care Devices Market in 2025, with demand concentrated in higher-income markets that support better access to monitoring. Reimbursement and affordability constraints limit broader uptake across many countries, even as diabetes prevalence increases. Distribution reach and education support remain critical to building sustained adoption. Vendors often rely on partnerships and targeted channel strategies to expand access.
Competitive Landscape
Competition in the Diabetes Care Devices Market is defined by ecosystem-based strategies that combine hardware, software, and services to improve usability and clinical decision-making. Companies differentiate through sensor performance, wear comfort, interoperability with insulin delivery systems, and app and cloud experiences that support remote monitoring. Channel strength and patient support programs influence retention, particularly for users transitioning to advanced systems. Portfolio breadth across monitoring and therapy solutions supports cross-selling and long-term customer relationships.
Abbott focuses on scaling continuous glucose monitoring adoption through broad channel coverage, product iteration, and ecosystem integration that supports day-to-day diabetes management workflows. The company’s approach emphasizes user-friendly experiences that can improve adherence and persistence across diverse patient groups. Competitive positioning benefits from portfolio breadth and brand familiarity in glucose monitoring. Ongoing investment in integration and access supports expansion across both clinical and consumer-oriented pathways.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In April 2025, Medtronic announced that the U.S. FDA approved its Simplera Sync sensor for use with the MiniMed 780G system. The approval expanded Medtronic’s CGM options for its advanced insulin delivery platform, and the company said a limited U.S. launch would begin in fall 2025.
In April 2025, Abbott entered a partnership with Epic to integrate data from its Libre continuous glucose monitoring systems directly into Epic’s electronic health record systems in the United States. The collaboration is intended to simplify provider workflows through Epic’s Aura software and give clinicians easier access to glucose data inside routine care systems.
In November 2025, Dexcom announced that its Dexcom G7 15 Day continuous glucose monitoring system would launch in the United States on December 1, 2025 for adults with diabetes. Dexcom said the device provides real-time glucose readings for up to 15.5 days and would be compatible at launch with selected automated insulin delivery systems.
In January 2026, Senseonics announced that Eversense 365 received European approval and said the company expected to launch the one-year CGM in Germany, Italy, Spain, and Sweden in the following months. This update extended Senseonics’ expansion in implantable CGM technology beyond the U.S. market.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 29,384.61 million
Revenue forecast in 2032
USD 49,607.36 million
Growth rate (CAGR)
9.12% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
Device Category; Technology; Usage Mode; Patient Type; Distribution Channel; Data Integration
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled
Abbott; Dexcom; Medtronic; Roche; Insulet; Tandem Diabetes Care; Ascensia; Novo Nordisk; Eli Lilly; Sanofi
No. of Pages
332
By Segmentation
By Device Category
Glucose Meters
CGM
Insulin Pumps
By Technology
Connected
Non-connected
By Usage Mode
Continuous
Spot-check
By Patient Type
Type 1
Type 2
By Distribution Channel
Retail Pharmacy
DME
Online
By Data Integration
Standalone
App-connected
Cloud-integrated
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Diabetes Care Devices Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Device Category
6.1. Glucose Meters
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. CGM
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Insulin Pumps
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity 7. Market Breakup by Technology
7.1. Connected
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Non-connected
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity 8. Market Breakup by Usage Mode
8.1. Continuous
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Spot-check
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity 9. Market Breakup by Patient Type
9.1. Type 1
9.1.1. Market Trends
9.1.2. Market Forecast
9.1.3. Revenue Share
9.1.4. Revenue Growth Opportunity
9.2. Type 2
9.2.1. Market Trends
9.2.2. Market Forecast
9.2.3. Revenue Share
9.2.4. Revenue Growth Opportunity 10. Market Breakup by Distribution Channel
10.1. Retail Pharmacy
10.1.1. Market Trends
10.1.2. Market Forecast
10.1.3. Revenue Share
10.1.4. Revenue Growth Opportunity
10.2. DME
10.2.1. Market Trends
10.2.2. Market Forecast
10.2.3. Revenue Share
10.2.4. Revenue Growth Opportunity
10.3. Online
10.3.1. Market Trends
10.3.2. Market Forecast
10.3.3. Revenue Share
10.3.4. Revenue Growth Opportunity 11. Market Breakup by Data Integration
11.1. Standalone
11.1.1. Market Trends
11.1.2. Market Forecast
11.1.3. Revenue Share
11.1.4. Revenue Growth Opportunity
11.2. App-connected
11.2.1. Market Trends
11.2.2. Market Forecast
11.2.3. Revenue Share
11.2.4. Revenue Growth Opportunity
11.3. Cloud-integrated
11.3.1. Market Trends
11.3.2. Market Forecast
11.3.3. Revenue Share
11.3.4. Revenue Growth Opportunity 12. Market Breakup by Region
12.1. North America
12.1.1. United States
12.1.1.1. Market Trends
12.1.1.2. Market Forecast
12.1.2. Canada
12.1.2.1. Market Trends
12.1.2.2. Market Forecast
12.1.3. Mexico
12.1.3.1. Market Trends
12.1.3.2. Market Forecast
12.2. Europe
12.2.1. Germany
12.2.2. France
12.2.3. United Kingdom
12.2.4. Italy
12.2.5. Spain
12.2.6. Others
12.3. Asia-Pacific
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. South Korea
12.3.5. Australia
12.3.6. Others
12.4. Latin America
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Others
12.5. Middle East and Africa
12.5.1. Market Trends
12.5.2. Market Breakup by Country
12.5.3. Market Forecast 13. SWOT Analysis
13.1. Overview
13.2. Strengths
13.3. Weaknesses
13.4. Opportunities
13.5. Threats
14. Value Chain Analysis
15. Porter’s Five Forces Analysis
15.1. Overview
15.2. Bargaining Power of Buyers
15.3. Bargaining Power of Suppliers
15.4. Degree of Competition
15.5. Threat of New Entrants
15.6. Threat of Substitutes 16. Price Analysis 17. Competitive Landscape
17.1. Market Structure
17.2. Key Players
17.3. Profiles of Key Players
17.3.1. Abbott
17.3.1.1. Company Overview
17.3.1.2. Product Portfolio
17.3.1.3. Financials
17.3.1.4. SWOT Analysis
17.3.2. Dexcom
17.3.3. Medtronic
17.3.4. Roche
17.3.5. Insulet
17.3.6. Tandem Diabetes Care
17.3.7. Ascensia
17.3.8. Novo Nordisk
17.3.9. Eli Lilly
17.3.10. Sanofi 18. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size of the Diabetes Care Devices Market in 2025 and the forecast for 2032?
The Diabetes Care Devices Market was valued at USD 29,384.61 million in 2025. The Diabetes Care Devices Market is projected to reach USD 49,607.36 million by 2032.
What is the CAGR for the Diabetes Care Devices Market during 2025–2032?
The Diabetes Care Devices Market is expected to grow at a CAGR of 9.12% from 2025 to 2032. Growth is supported by higher monitoring intensity and technology adoption across care settings.
What is the largest segment in the Diabetes Care Devices Market?
Type 2 accounted for the largest share of 63.8% in 2025. The segment leads due to broad prevalence and recurring monitoring needs.
What factors are driving growth in the Diabetes Care Devices Market?
Rising diabetes prevalence, earlier diagnosis, and the shift toward continuous monitoring are key drivers. Connected ecosystems and channel expansion are reinforcing device adoption and retention.
Which companies are leading in the Diabetes Care Devices Market?
Key companies include Abbott, Dexcom, Medtronic, Roche, and Insulet. The market also includes Tandem Diabetes Care, Ascensia, Novo Nordisk, Eli Lilly, and Sanofi.
Which region leads the Diabetes Care Devices Market?
North America led the Diabetes Care Devices Market with a 41.7% share in 2025. Leadership is supported by strong reimbursement depth and high adoption of advanced monitoring and delivery technologies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Cell Cytometry market size was valued USD 5,659 Million in 2024 and is anticipated to reach USD 10,319.51 Million by 2032, at a CAGR of 7.8% during the forecast period.
Blood Meal Market size was valued USD 8,920 Million in 2024 and is anticipated to reach USD 14,542.23 Million by 2032, at a CAGR of 6.3% during the forecast period.
The Audiology Devices market size reached USD 14,763 million in 2024. It is expected to reach USD 23,655.31 million by 2032, at a CAGR of 6.07% during the forecast period.
The diagnostic specialty antibodies market was valued at USD 4,093 million in 2024 and is projected to reach USD 7,860.6 million by 2032, expanding at a compound annual growth rate (CAGR) of 8.5% during the forecast period.
Novel Spectrometry Platforms Market size was valued USD 2219 million in 2024 and is anticipated to reach USD 3430.76 million by 2032, at a CAGR of 5.6% during the forecast period.
Coronary Microcatheters Market size was valued USD 2180 million in 2024 and is anticipated to reach USD 3100.18 million by 2032, at a CAGR of 4.5% during the forecast period.
The Disability Devices Market size was estimated at USD 21,480.60 million in 2025 and is expected to reach USD 33,935.80 million by 2032, growing at a CAGR of 7.92% from 2025 to 2032.
The Global Disposable Gloves Market is projected to grow from USD18,873.30 million in 2024 to an estimated USD34,973.61 million based on 2032, with a compound annual growth rate (CAGR) of 8.08% from 2025 to 2032.
The Disposable Medical Devices Sensors Market size was estimated at USD 4,860.25 million in 2025 and is expected to reach USD 9,926.92 million by 2032, growing at a CAGR of 12.64% from 2025 to 2032.
The home rehabilitation products and services market size was valued at USD 99,942.46 million in 2024 and is expected to reach USD 167,905.7 million by 2032, registering a CAGR of 6.7% during the forecast period.
The Global mRNA Vaccine and Therapeutics Market size was valued at USD 7,800.00 million in 2018 to USD 13,444.94 million in 2024 and is anticipated to reach USD 46,668.48 million by 2032, at a CAGR of 16.93% during the forecast period.
Orthopedic Oncology Treatment Market size was valued USD 1310 million in 2024 and is anticipated to reach USD 2135.79 million by 2032, at a CAGR of 6.3% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
